Rafael Holdings, Inc.
AI Executive Summary
AI-powered analysis of 10-Q filing content
Rafael Holdings shows severe financial deterioration with massive R&D spending increases, declining cash position, and persistent operational losses. The company burned through $15M in cash in 6 months while dramatically scaling up clinical trial activities, raising serious concerns about runway and cash management.
Red Flags Detected (6)
Cash declined $15M (28%) from $52.8M to $37.8M in 6 months
R&D expenses exploded 428% to $12M from $2.3M year-over-year
Operating losses worsened 60% to $16.8M from $10.5M
3 more red flags detected
Key Takeaways
Company is in aggressive clinical development phase with unsustainable cash burn
Current cash may last less than 2 years at current spending levels
2 more takeaways
Filing Overview
What This Means
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.